3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
28
Cyclophosphamide
14
Nivolumab
13
Paclitaxel
7
fludarabine
6
Specimen Handling
5
aldesleukin
4
Taxes
4
Ipilimumab
4
Interleukin-2
4
Gemcitabine
4
Drug Therapy
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
poly ICLC
3
liposomal doxorubicin
3
epacadostat
3
cobimetinib
3
cemiplimab
3
Magnetic Resonance Spectroscopy
3
Injections
3
Cisplatin
3
veliparib
2
ulixertinib
2
sargramostim
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Technetium-99
×
Dermatologic
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled